Search Within

Oscar Boutros Lahoud

Formats
  1. Meeting Abstract (88)
  2. Journal Article (37)
  3. Research Letter (6)
  4. Correspondence (2)
  5. Review (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (130)
  4. Survivorship Research (126)
  5. Bone Marrow Transplant (124)
  6. CTCR Scholars (113)

More Groups

People
  1. Sergio Giralt (108)
  2. Gunjan Shah (106)
  3. Heather Landau (103)
  4. Michael Scordo (99)
  5. David Chung (93)
  6. Hani Hassoun (89)

More People

Years
  1. 2025 (2)
  2. 2024 (12)
  3. 2023 (42)
  4. 2022 (28)
  5. 2021 (10)
  6. 2020 (18)

More Years

Publications
  1. Blood (47)
  2. Clinical Lymphoma, Myeloma and Leukemia (26)
  3. Biology of Blood and Marrow Transplantation (10)
  4. Blood Advances (9)
  5. Journal of Clinical Oncology (8)
  6. Leukemia and Lymphoma (6)

More Publications

Publishers
  1. American Society of Hematology (56)
  2. Elsevier Inc. (41)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (7)
  5. Taylor & Francis Group (6)
  6. John Wiley & Sons (3)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
    Journal Article

    Nath, K.; Shekarkhand, T.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D. J.; Landau, H. J.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naìˆve multiple myeloma
    Journal Article

    Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
    Journal Article

    Costa, B. A.; Flynn, J.; Nishimura, N.; Devlin, S. M.; Farzana, T.; Rajeeve, S.; Chung, D. J.; Landau, H. J.; Lahoud, O. B.; Scordo, M.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation
    Research Letter

    Stuver, R.; Mian, A.; Brown, S.; Devlin, S.; Caimi, P. F.; Chinapen, S.; Dahi, P.; Dean, R.; Epstein-Peterson, Z. D.; Hill, B.; more...
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Longitudinal assessment of minimal residual disease (MRD) in the ATLAS randomized phase 3 trial of post-transplant treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide (R) alone in patients with newly diagnosed multiple myeloma (NDMM)
    Meeting Abstract

    Kubicki, T.; Dytfeld, D.; Wrobel, T.; Jamroziak, K.; Robak, P.; Czyz, J.; Tyczynska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Nowicki, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Artificial intelligence enabled ECG interpretation informs outcomes after autologous transplantation for multiple myeloma
    Meeting Abstract

    Shaffer, B. C.; Attia, I. Z.; Greason, G.; Chinapen, S.; Brown, S.; Chung, D.; Lahoud, O. B.; Lopez-Jimenez, F.; Schaffer, W.; Liu, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save